Aravive (NASDAQ:ARAV – Get Rating) had its price objective boosted by equities researchers at HC Wainwright from $7.00 to $12.00 in a research note issued to investors on Wednesday, The Fly reports. The firm presently has a “buy” rating on the stock.
Separately, EF Hutton Acquisition Co. I restated a “buy” rating and set a $10.00 price objective on shares of Aravive in a research note on Tuesday, February 14th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Aravive presently has a consensus rating of “Buy” and an average target price of $9.20.
Aravive Stock Up 13.7 %
Shares of NASDAQ ARAV opened at $1.83 on Wednesday. Aravive has a fifty-two week low of $0.58 and a fifty-two week high of $2.23. The firm’s 50-day simple moving average is $1.83 and its 200 day simple moving average is $1.40. The stock has a market cap of $109.49 million, a P/E ratio of -0.78 and a beta of 2.35.
Institutional Trading of Aravive
Aravive, Inc operates as a clinical stage biotechnology company. The firm engages in the development of new therapies that target important survival pathways for both advanced solid tumors as well as hematologic malignancies. Its product candidate, Aravive-S6, is a soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL which also promotes metastasis, cancer cell survival, resistance to treatments and immune suppression.
- Get a free copy of the StockNews.com research report on Aravive (ARAV)
- Don’t Miss Out: $2 Trillion Could be Headed to the Banking Sector
- A Weakening Economy Suggests Caution Before Buying Five Below
- Williams-Sonoma: Time To Buy At Rock-Bottom Prices
- Why DraftKings Could Keep Outperforming in 2023
- Charles Schwab And The Safest 30% You Can Make This Year
Receive News & Ratings for Aravive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aravive and related companies with MarketBeat.com's FREE daily email newsletter.